Pocketing $68M, PacBio Remains on Track for Commercial Launch — and Possible IPO — in 2010
August 18, 2009
Pocketing $68M, PacBio Remains on Track for Commercial Launch — and Possible IPO — in 2010
The funding will support PacBio's effort to launch its SMRT sequencing system in the second half of 2010, and will also serve as a financial "buffer" as the company looks to pursue an initial public offering or other large-scale financing effort some time next year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PacBio Looks to Raise up to $200M in IPO; Reports $15M Order Backlog
August 24, 2010 / In Sequence - PacBio to Expand Apps for SMRT Platform; Initial Focus on Cancer, Infectious Disease Sequencing
September 22, 2009 / In Sequence - PacBio Raises IPO Target to $230M, Enacts 1-for-2 Reverse Stock Split, Prices Shares
October 5, 2010 / In Sequence - PacBio Says It Will 'Vigorously' Defend Against Helicos' Patent Infringement Claims
September 7, 2010 / In Sequence - PacBio Shows Proof of Principle for Methylation Sequencing, Direct RNA Sequencing
September 22, 2009 / In Sequence